These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 29028973

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial.
    Manjaly Thomas ZR, Satti I, Marshall JL, Harris SA, Lopez Ramon R, Hamidi A, Minhinnick A, Riste M, Stockdale L, Lawrie AM, Vermaak S, Wilkie M, Bettinson H, McShane H.
    PLoS Med; 2019 Apr; 16(4):e1002790. PubMed ID: 31039172
    [Abstract] [Full Text] [Related]

  • 3. The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.
    Tameris M, Geldenhuys H, Luabeya AK, Smit E, Hughes JE, Vermaak S, Hanekom WA, Hatherill M, Mahomed H, McShane H, Scriba TJ.
    PLoS One; 2014 Apr; 9(2):e87340. PubMed ID: 24498312
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial.
    Satti I, Meyer J, Harris SA, Manjaly Thomas ZR, Griffiths K, Antrobus RD, Rowland R, Ramon RL, Smith M, Sheehan S, Bettinson H, McShane H.
    Lancet Infect Dis; 2014 Oct; 14(10):939-46. PubMed ID: 25151225
    [Abstract] [Full Text] [Related]

  • 7. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial.
    Ndiaye BP, Thienemann F, Ota M, Landry BS, Camara M, Dièye S, Dieye TN, Esmail H, Goliath R, Huygen K, January V, Ndiaye I, Oni T, Raine M, Romano M, Satti I, Sutton S, Thiam A, Wilkinson KA, Mboup S, Wilkinson RJ, McShane H, MVA85A 030 trial investigators.
    Lancet Respir Med; 2015 Mar; 3(3):190-200. PubMed ID: 25726088
    [Abstract] [Full Text] [Related]

  • 8. Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial.
    Tameris M, Mearns H, Penn-Nicholson A, Gregg Y, Bilek N, Mabwe S, Geldenhuys H, Shenje J, Luabeya AKK, Murillo I, Doce J, Aguilo N, Marinova D, Puentes E, Rodríguez E, Gonzalo-Asensio J, Fritzell B, Thole J, Martin C, Scriba TJ, Hatherill M, MTBVAC Clinical Trial Team.
    Lancet Respir Med; 2019 Sep; 7(9):757-770. PubMed ID: 31416768
    [Abstract] [Full Text] [Related]

  • 9. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa.
    Hawkridge T, Scriba TJ, Gelderbloem S, Smit E, Tameris M, Moyo S, Lang T, Veldsman A, Hatherill M, Merwe Lv, Fletcher HA, Mahomed H, Hill AV, Hanekom WA, Hussey GD, McShane H.
    J Infect Dis; 2008 Aug 15; 198(4):544-52. PubMed ID: 18582195
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. MVA85A vaccine to enhance BCG for preventing tuberculosis.
    Kashangura R, Jullien S, Garner P, Johnson S.
    Cochrane Database Syst Rev; 2019 Apr 30; 4(4):CD012915. PubMed ID: 31038197
    [Abstract] [Full Text] [Related]

  • 16. Heterologous vaccination against human tuberculosis modulates antigen-specific CD4+ T-cell function.
    Dintwe OB, Day CL, Smit E, Nemes E, Gray C, Tameris M, McShane H, Mahomed H, Hanekom WA, Scriba TJ.
    Eur J Immunol; 2013 Sep 30; 43(9):2409-20. PubMed ID: 23737382
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The impact of HIV exposure and maternal Mycobacterium tuberculosis infection on infant immune responses to bacille Calmette-Guérin vaccination.
    Jones CE, Hesseling AC, Tena-Coki NG, Scriba TJ, Chegou NN, Kidd M, Wilkinson RJ, Kampmann B.
    AIDS; 2015 Jan 14; 29(2):155-65. PubMed ID: 25535752
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Cellular immune responses induced in cattle by heterologous prime-boost vaccination using recombinant viruses and bacille Calmette-Guérin.
    Vordermeier HM, Rhodes SG, Dean G, Goonetilleke N, Huygen K, Hill AV, Hewinson RG, Gilbert SC.
    Immunology; 2004 Jul 14; 112(3):461-70. PubMed ID: 15196215
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.